MDRC.BO · BSE
MODERN DIAGNOSTIC & RESEARCH C
₹83
-1.13% (-₹0.95)
Prev. close
₹83.95
Volume
30,400
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About MODERN DIAGNOSTIC & RESEARCH C
Modern Diagnostic & Research Centre Limited provides diagnostic and related healthcare tests services to individuals, healthcare institutions, doctors, corporates and other institutional customers in India. It offers lab services, which includes molecular diagnostics and oncogenomics, cytogenetics, histopathology and cytopathology, microbiology, hematology and coagulation, biochemistry, allergy testing, serology and immunology, hormonal assays, cervical cancer screening, maternal screening markers, clinical pathology, autoimmune profile services. The company also provides radiology services, such as magnetic resonance imaging, computerized tomography scan (CT) scans, PET-CT, ultrasound, cardiology, color Doppler studies, digital X-rays, mammography, bone screen, Nerve conduction velocity, interventional radiology, heart lab, neuro lab and laboratory, electrocardiogram, cone beam CT, orthopantomogram, pulmonary function tests, etc. In addition, it offers Specialised Genetic & Molecular Services. The company was founded in 1985 and is based in Gurugram, India.
Details
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Dr. Devendra Singh Yadav
Headquarters
Gurugram
Employees
616
Website
mdrcindia.comExchange
View on BSE ↗Key stats
Market cap
₹125.32 Cr
P/E ratio (TTM)
23.9
EPS (TTM)
₹3.48
Shares float
40.99 L
EPS · quarter ended Jun 2025
₹1.99
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹56.28 Cr | ₹67.13 Cr | ₹77.95 Cr | ₹83.11 Cr | |
| EBITDA | ₹-69.16 L | ₹12.57 Cr | ₹18.91 Cr | ₹13.62 Cr |
| ₹-5.73 Cr | ₹5.79 Cr | ₹9.01 Cr | ₹5.25 Cr | |
| Diluted EPS | ₹-3.8 | ₹3.84 | ₹5.97 | ₹3.48 |
Total expenses (as filed), Employee benefit expense, Other expenses have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹36.54 Cr | ₹49.49 Cr | ₹64.57 Cr | ₹118.60 Cr | |
| ₹15.31 Cr | ₹20.46 Cr | ₹22.09 Cr | ₹37.10 Cr | |
| Stockholders' equity | ₹5.96 Cr | ₹11.76 Cr | ₹20.77 Cr | ₹58.55 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹-11.89 L | ₹7.93 Cr | ₹13.90 Cr | ₹3.82 Cr | |
| Investing cash flow | ₹2.11 Cr | ₹-11.03 Cr | ₹-13.31 Cr | ₹-40.29 Cr |
| Financing cash flow | ₹-6.47 Cr | ₹3.36 Cr | ₹-21.74 L | ₹45.08 Cr |
| Capital expenditure | ₹-3.33 Cr | ₹-11.03 Cr | ₹-13.32 Cr | ₹-23.70 Cr |
| End cash position | ₹15.38 L | ₹41.23 L | ₹78.42 L | ₹9.40 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| MODERN DIAGNOSTIC & RESEARCH C | ₹123.44 Cr | ₹83 | 23.5 | 2.11 | 9.0% | 0.63 | +6.6% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.